Table 1.
Demographic, clinical, and pathological characteristics of prostate cancer cases by race
| Black (n=628) | Non-black (n=1020) | p-value | |
|---|---|---|---|
| Age, mean ± SD | 59.7 (6.4) | 62.3 (5.8) | <0.001 |
|
| |||
| Year of surgery, median (Q1–Q3) | 2009 (2005–2011) | 2009 (2004–2011) | 0.407 |
|
| |||
| Follow-up (years), median (Q1–Q3) | 2.7 (1.2–6.0) | 3.0 (1.5–6.3) | 0.046 |
|
| |||
| PSA (ng/ml), median (Q1–Q3) | 6.6 (4.9–10.2) | 6.2 (4.7–8.8) | 0.001 |
|
| |||
| Pathological Gleason score, n (%) | |||
| 2−6 | 148 (24) | 281 (28) | 0.001 |
| 7 (3+4) | 284 (45) | 369 (36) | |
| 7 (4+3)−10 | 196 (31) | 370 (36) | |
|
| |||
| Positive margins, n (%) | 273 (43) | 369 (36) | 0.003 |
|
| |||
| Extracapsular extension, n (%) | 109 (17) | 209 (20) | 0.117 |
|
| |||
| Seminal vesicle invasion, n (%) | 70 (11) | 90 (9) | 0.122 |
|
| |||
| Positive lymph nodes, n (%) | 20 (3) | 21 (2) | 0.297 |
|
| |||
| BMI (kg/m2), median (Q1–Q3) | 27.7 (24.8–31.0) | 28.1 (25.4–31.0) | 0.122 |
|
| |||
| Diabetes*, n (%) | 65 (13) | 75 (13) | 0.912 |
|
| |||
| Total cholesterol (mg/dl), mean ± SD | 186.3 (38.4) | 186.6 (35.5) | 0.855 |
|
| |||
| LDL (mg/dl), mean ± SD | 111.6 (32.9) | 114.1 (31.8) | 0.121 |
|
| |||
| HDL (mg/dl), mean ± SD | 50.0 (18.0) | 44.5 (15.0) | <0.001 |
|
| |||
| Triglycerides (mg/dl), mean ± SD | 124.6 (84.2) | 144.2 (105.4) | <0.001 |
|
| |||
| Statin use, n (%) | |||
| Never use | 509 (81) | 839 (82) | 0.538 |
| Postoperative use | 119 (19) | 181 (18) | |
BMI=body mass index; HDL=high-density lipoprotein; LDL=low density lipoprotein; PSA=prostate specific antigen; SD=standard deviation; Q1=25th percentile; Q3=75th percentile
*
missing for n=596 (36%) of cases